Title:Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors
Volume: 24
Issue: 4
Author(s): Laxmi Banjare*
Affiliation:
- School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur, 495009 (C.G.) India
- Shri Shankaracharya Institute
of Pharmaceutical Sciences and Research, Bhilai, 490020, India
Keywords:
3D-QSAR, letrozole, aromatse, aromatase inhibitors, breast cancer, triazole analogues.
Abstract:
Background: In current scenario breast cancer measured as one of the dangerous health issues. An
effective therapeutic class of drug known as aromatase inhibitors (AIs) is dominant against estrogen receptorpositive
breast cancer. However, there is an urgent need to create target-specific AIs with better anti-breast cancer
profiles due to the increased toxicity and adverse effects related to currently existing anti-breast cancer drugs.
Objectives: In the present study, we have designed of 100 novel tiazole analogues as aromatase inhibitors their
pharmacophoric features were explored.
Method: Molecular docking was applied to a series of 4-substituted-1, 2, 3-triazoles containing letrozole for their
aromatase inhibitory effects. The aromatase inhibitory activity of the compound in a series varies in the range of
(IC50 = 0.008–31.26 μM). A hydrogen atom positioned at R1 of the triazole ring in compound (01) was responsible
for the most potent compound (IC50 = 0.008 μM) in the series of 28 compounds as compared to letrozole. The
self-organizing molecular field study was used to assess the molecular characteristics and biological activities of
the compounds. The four models were developed using PLS and MLR methods. The PLS method was good for
statistical analysis. The letrozole scaffold-based 100 compounds were designed by selecting an effective pharmacophore
responsible for aromatase inhibitory activity. The designed compound was placed on the previous model
as a test set, and its IC50 values were calculated.
Result: Hydrogen bonds were established between the potent molecule (01) and the essential residues Met 374
and Arg 115, which were responsible for the aromatase-inhibiting action. Cross-validated q2 (0.6349) & noncross-
validated r2 (0.7163) were discovered in the statistical findings as having reliable predictive power. Among
100 designed compounds, seven compounds showed good aromatase inhibitory activities.
Conclusion: The additional final SOMFA model created for the interactions between the aromatase and the triazole
inhibitors may be helpful for future modification and enhancement of the inhibitors of this crucial enzyme.
